ClinicalTrials.gov
ClinicalTrials.gov Menu

Stem Cell Therapy for Cerebral Palsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01978821
Recruitment Status : Completed
First Posted : November 8, 2013
Last Update Posted : September 26, 2016
Sponsor:
Information provided by (Responsible Party):
Neurogen Brain and Spine Institute

October 25, 2013
November 8, 2013
September 26, 2016
August 2010
August 2013   (Final data collection date for primary outcome measure)
Change in clinical symptoms of cerebral palsy after 6 months [ Time Frame: Six months ]
Same as current
Complete list of historical versions of study NCT01978821 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Stem Cell Therapy for Cerebral Palsy
Open Label Study of Autologous Bone Marrow Mononuclear Cells in Cerebral Palsy
the purpose of this study was to study the effect of stem cell therapy on common symptoms of cerebral palsy patients.
Not Provided
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Cerebral Palsy
Procedure: Autologous bone marrow mononuclear cell transplantation
Experimental: stem cell
autologous bone marrow mononuclear cell transplantation
Intervention: Procedure: Autologous bone marrow mononuclear cell transplantation

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
Same as current
August 2013
August 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosed cases of any type of Cerebral Palsy
  • age above 12 months.

Exclusion Criteria:

  • presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/Hepatitis C Virus
  • malignancies
  • bleeding tendencies
  • pneumonia
  • renal failure
  • severe liver dysfunction
  • severe anemia [Hemoglobin < 8]
  • any bone marrow disorder
  • space occupying lesion in brain
  • other acute medical conditions such as respiratory infection and pyrexia.
Sexes Eligible for Study: All
17 Months to 22 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
India
 
 
NCT01978821
NGBSI-01
Yes
Not Provided
Not Provided
Neurogen Brain and Spine Institute
Neurogen Brain and Spine Institute
Not Provided
Not Provided
Neurogen Brain and Spine Institute
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP